Tags

Type your tag names separated by a space and hit enter

Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice.
Cancer Res. 1998 Sep 15; 58(18):4127-31.CR

Abstract

Innovative, more effective treatment modalities are needed for Ewing's sarcoma (ES), a neoplasm with a disappointingly low survival rate despite the use of aggressive multimodal therapeutic approaches. We have previously shown (K. Scotlandi et al, Cancer Res., 56: 4570-4574, 1996) the existence and the pathogenetic relevance of an autocrine loop that is mediated by the insulin-like growth factor-I receptor (IGF-IR) and is crucial for the survival and proliferation of ES cells in vitro. In this study, we report that the IGF-IR-blocking monoclonal antibody alphaIR3 may also significantly inhibit ES cell growth in vivo. In particular, in almost one-half of the animals tested, after s.c. inoculation with TC-71 ES cells, the blockage of IGF-IR by alphaIR3 induced a complete regression of tumors that developed, which suggests that IGF-IR is valuable as a specific target for novel therapeutic strategies. In addition, suramin, a drug that can interfere with growth factor binding with their receptors, inhibited the tumorigenic and the metastatic ability of TC-71 cells and, therefore, is a promising agent to be combined with conventional cytotoxic drugs for the design of more effective therapeutic regimens.

Authors+Show Affiliations

Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9751624

Citation

Scotlandi, K, et al. "Blockage of Insulin-like Growth factor-I Receptor Inhibits the Growth of Ewing's Sarcoma in Athymic Mice." Cancer Research, vol. 58, no. 18, 1998, pp. 4127-31.
Scotlandi K, Benini S, Nanni P, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. 1998;58(18):4127-31.
Scotlandi, K., Benini, S., Nanni, P., Lollini, P. L., Nicoletti, G., Landuzzi, L., Serra, M., Manara, M. C., Picci, P., & Baldini, N. (1998). Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Research, 58(18), 4127-31.
Scotlandi K, et al. Blockage of Insulin-like Growth factor-I Receptor Inhibits the Growth of Ewing's Sarcoma in Athymic Mice. Cancer Res. 1998 Sep 15;58(18):4127-31. PubMed PMID: 9751624.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. AU - Scotlandi,K, AU - Benini,S, AU - Nanni,P, AU - Lollini,P L, AU - Nicoletti,G, AU - Landuzzi,L, AU - Serra,M, AU - Manara,M C, AU - Picci,P, AU - Baldini,N, PY - 1998/9/29/pubmed PY - 1998/9/29/medline PY - 1998/9/29/entrez SP - 4127 EP - 31 JF - Cancer research JO - Cancer Res VL - 58 IS - 18 N2 - Innovative, more effective treatment modalities are needed for Ewing's sarcoma (ES), a neoplasm with a disappointingly low survival rate despite the use of aggressive multimodal therapeutic approaches. We have previously shown (K. Scotlandi et al, Cancer Res., 56: 4570-4574, 1996) the existence and the pathogenetic relevance of an autocrine loop that is mediated by the insulin-like growth factor-I receptor (IGF-IR) and is crucial for the survival and proliferation of ES cells in vitro. In this study, we report that the IGF-IR-blocking monoclonal antibody alphaIR3 may also significantly inhibit ES cell growth in vivo. In particular, in almost one-half of the animals tested, after s.c. inoculation with TC-71 ES cells, the blockage of IGF-IR by alphaIR3 induced a complete regression of tumors that developed, which suggests that IGF-IR is valuable as a specific target for novel therapeutic strategies. In addition, suramin, a drug that can interfere with growth factor binding with their receptors, inhibited the tumorigenic and the metastatic ability of TC-71 cells and, therefore, is a promising agent to be combined with conventional cytotoxic drugs for the design of more effective therapeutic regimens. SN - 0008-5472 UR - https://www.unboundmedicine.com/medline/citation/9751624/Blockage_of_insulin_like_growth_factor_I_receptor_inhibits_the_growth_of_Ewing's_sarcoma_in_athymic_mice_ L2 - http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=9751624 DB - PRIME DP - Unbound Medicine ER -